البلد: كندا
اللغة: الفرنسية
المصدر: Health Canada
Pimobendan
BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
10MG
Comprimé (à mâcher)
Pimobendan 10MG
Orale
50
Prescription
Chiens
Numéro de groupe d'ingrédients actifs (GIA) :0149543004
APPROUVÉ
2020-09-29
VETMEDIN ® CHEWABLE TABLETS – 1.25 MG, 2.5 MG, 5.0 MG AND 10 MG BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. – CLEAN VERSION BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. PAGE 1 OF 14 SUBMITTED AUGUST 27, 2020 1.25 MG, 2.5 MG, 5.0 MG AND 10 MG CARTONS - ENGLISH FRONT (MAIN) PANEL: DIN (02469480) (02469499) (02469502) (02469464) PR VETMEDIN ® (1.25 MG) (2.5 MG) (5.0 MG) (10 MG) CHEWABLE TABLETS pimobendan chewable tablets FOR VETERINARY USE ONLY FOR DOGS NET CONTENTS: 50 CHEWABLE TABLETS (BI Logo on the bottom) SIDE PANEL: ACTIVE INGREDIENT: PIMOBENDAN (1.25 MG) (2.5 MG) (5.0 MG) (10 MG) PER TABLET See package insert for complete prescribing information. INDICATIONS: Dogs: For the treatment of congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency. It is recommended that the diagnosis of congestive heart failure be confirmed by radiographs or diuretic responsiveness. Treatment should be initiated only in symptomatic cases which will benefit from increased myocardial contractility (positive inotropy). DOSAGE AND ADMINISTRATION : Daily oral administration at a dose range of 0.2 mg to 0.6 mg pimobendan/kg body weight. The preferable daily dose is 0.5 mg/kg body weight. The dose should be divided into two administrations at approximately 12h intervals. Each dose should be given approximately one hour before feeding. Vetmedin ® chewable tablets may be combined with a diuretic treatment such as furosemide in dogs with pulmonary edema and/or ascites associated with congestive heart failure. CAUTION : Cardiac arrhythmias may indicate a more guarded prognosis. Dogs should be monitored for presence of arrhythmias during therapy. Appropriate anti-arrhythmic should be initiated if indicated. CONTRA-INDICATIONS: Should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). WARNING: KEEP OUT OF REACH OF CHILDREN. STORAGE: Protect from moisture. S اقرأ الوثيقة كاملة